111In-labeled trastuzumab-modified gold nanoparticles are cytotoxic in vitro to HER2-positive breast cancer cells and arrest tumor growth in vivo in athymic mice after intratumoral injection

Cai, Zhongli; Chattopadhyay, Niladri; Yang, Kaiyun; Kwon, Yongkyu Luke; Yook, Simmyung; Pignol, Jean-Philippe; Reilly, Raymond M.

doi:10.1016/j.nucmedbio.2016.08.009

Cited by 66 publications

(58 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, the uptake of bioconjugated nanoparticles in cells with overexpressed receptors greatly increases. Unfortunately, the limitation of intravenously administrated NPs is their sequestration by the liver, lungs, and spleen, causing rapid elimination from the blood, radiation exposure of these organs and low tumor uptake [10].…”

Section: Introductionmentioning

confidence: 99%

Trastuzumab Conjugated Superparamagnetic Iron Oxide Nanoparticles Labeled with 225Ac as a Perspective Tool for Combined α-Radioimmunotherapy and Magnetic Hyperthermia of HER2-Positive Breast Cancer

et al. 2020

View full text Add to dashboard Cite

It has been proven and confirmed in numerous repeated tests, that the use of a combination of several therapeutic methods gives much better treatment results than in the case of separate therapies. Particularly promising is the combination of ionizing radiation and magnetic hyperthermia in one drug. To achieve this objective, magnetite nanoparticles have been modified in their core with α emitter 225Ac, in an amount affecting only slightly their magnetic properties. By 3-phosphonopropionic acid (CEPA) linker nanoparticles were conjugated covalently with trastuzumab (Herceptin®), a monoclonal antibody that recognizes ovarian and breast cancer cells overexpressing the HER2 receptors. The synthesized bioconjugates were characterized by transmission electron microscopy (TEM), Dynamic Light Scattering (DLS) measurement, thermogravimetric analysis (TGA) and application of 131I-labeled trastuzumab for quantification of the bound biomolecule. The obtained results show that one 225Ac@Fe3O4-CEPA-trastuzumab bioconjugate contains an average of 8–11 molecules of trastuzumab. The labeled nanoparticles almost quantitatively retain 225Ac (>98%) in phosphate-buffered saline (PBS) and physiological salt, and more than 90% of 221Fr and 213Bi over 10 days. In human serum after 10 days, the fraction of 225Ac released from 225Ac@Fe3O4 was still less than 2%, but the retention of 221Fr and 213Bi decreased to 70%. The synthesized 225Ac@Fe3O4-CEPA-trastuzumab bioconjugates have shown a high cytotoxic effect toward SKOV-3 ovarian cancer cells expressing HER2 receptor in-vitro. The in-vivo studies indicate that this bioconjugate exhibits properties suitable for the treatment of cancer cells by intratumoral or post-resection injection. The intravenous injection of the 225Ac@Fe3O4-CEPA-trastuzumab radiobioconjugate is excluded due to its high accumulation in the liver, lungs and spleen. Additionally, the high value of a specific absorption rate (SAR) allows its use in a new very perspective combination of α radionuclide therapy with magnetic hyperthermia.

show abstract

Section: Introductionmentioning

confidence: 99%

Trastuzumab Conjugated Superparamagnetic Iron Oxide Nanoparticles Labeled with 225Ac as a Perspective Tool for Combined α-Radioimmunotherapy and Magnetic Hyperthermia of HER2-Positive Breast Cancer

et al. 2020

View full text Add to dashboard Cite

show abstract

“…[11][12][13][14] Nanoparticle drugs have been exploited to circumvent the low bioavailability, rapid degradation and inactivation of drugs, and can rapidly enhance the permeability and retention (EPR) effect, and their ability to reduce the off-target toxicities of chemotherapeutics in tumors has been explored, leading to safe delivery systems and stable efficacy. [15][16][17][18] Recently, the use of UAloaded poly-D,L-lactic-co-glycolic acid nanoparticles (UA-NPs) as drug carrier was evaluated for differential tumor targeting effects in B16F10 melanoma cells. Smooth spherical nanoparticles of small size with relatively narrow size distribution ($154 nm) were produced through a single emulsication technique, and about 4% drug-loading efficiency and high encapsulation efficiency ($40%) were obtained.…”

Section: Introductionmentioning

confidence: 99%

Self-assembled nanoparticles based on a carboxymethylcellulose–ursolic acid conjugate for anticancer combination therapy

Liu

et al. 2017

RSC Adv.

View full text Add to dashboard Cite

show abstract

“…Table 4 summarizes a number of recent studies on HER2-targeted nanomedicine. [55][56][57][58][59] Although HER2 antibody is a targeting moiety commonly used for HER2+ cancer, other HER2 targeting ligands have also been studied. For instance, Ding et al used trastuzumab-mimetic peptide with promising results, and suggested that this may reduce the immunogenicity, production costs and technical efforts associated with the antibody.…”

Section: Latest Trend For the Development Of Nanomedicine-based Breasmentioning

confidence: 99%

Nanomedicine applications in the treatment of breast cancer: current state of the art

Xue

et al. 2017

IJN

152

View full text Add to dashboard Cite

Breast cancer is the most common malignant disease in women worldwide, but the current drug therapy is far from optimal as indicated by the high death rate of breast cancer patients. Nanomedicine is a promising alternative for breast cancer treatment. Nanomedicine products such as Doxil ® and Abraxane ® have already been extensively used for breast cancer adjuvant therapy with favorable clinical outcomes. However, these products were originally designed for generic anticancer purpose and not specifically for breast cancer treatment. With better understanding of the molecular biology of breast cancer, a number of novel promising nanotherapeutic strategies and devices have been developed in recent years. In this review, we will first give an overview of the current breast cancer treatment and the updated status of nanomedicine use in clinical setting, then discuss the latest important trends in designing breast cancer nanomedicine, including passive and active cancer cell targeting, breast cancer stem cell targeting, tumor microenvironment-based nanotherapy and combination nanotherapy of drug-resistant breast cancer. Researchers may get insight from these strategies to design and develop nanomedicine that is more tailored for breast cancer to achieve further improvements in cancer specificity, antitumorigenic effect, antimetastasis effect and drug resistance reversal effect.

show abstract

111In-labeled trastuzumab-modified gold nanoparticles are cytotoxic in vitro to HER2-positive breast cancer cells and arrest tumor growth in vivo in athymic mice after intratumoral injection

Abstract: A local radiation treatment for HER2-positive BC based on AuNP modified with trastuzumab and labeled with the Auger electron-emitter, In was developed and shown to arrest tumor growth with no normal tissue toxicity.

Cited by 66 publications

References 28 publications

Trastuzumab Conjugated Superparamagnetic Iron Oxide Nanoparticles Labeled with 225Ac as a Perspective Tool for Combined α-Radioimmunotherapy and Magnetic Hyperthermia of HER2-Positive Breast Cancer

Trastuzumab Conjugated Superparamagnetic Iron Oxide Nanoparticles Labeled with 225Ac as a Perspective Tool for Combined α-Radioimmunotherapy and Magnetic Hyperthermia of HER2-Positive Breast Cancer

Self-assembled nanoparticles based on a carboxymethylcellulose–ursolic acid conjugate for anticancer combination therapy

Nanomedicine applications in the treatment of breast cancer: current state of the art

Contact Info

Product

Resources

About